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Background: Epidermal growth factor receptor (EGFR) mutations
in non-small cell lung cancer (NSCLC) predict better outcome to
EGFR tyrosine kinase inhibitors. The most common mutations are
exon 19 deletions (most frequently E746–A750) and L858R point
mutation in exon 21. Here, we evaluated the accuracy of novel
EGFR mutation-specific antibodies in a Japanese cohort with
NSCLC and compared with direct DNA sequencing and clinical
outcome.
Materials and Methods: Immunohistochemistry (IHC) using anti-
bodies specific for the E746–A750 and L858R mutations in EGFR
was performed on tissue microarrays of tumors from 70 gefitinib
treated NSCLC patients. Extracted DNA was sequenced for muta-
tional analysis of EGFR exons 18 to 21.
Results: DNA sequencing showed EGFR mutations in 41 patients
(58.6%) and exon 19 deletions in 18 patients (25.7%), 11 of 18
(61%) had a deletion in the range of E746–A750 and 12 (17.1%) had
exon 21 mutations (L858R). IHC showed, for the E746–A750 and
L858R mutations, sensitivity (81.8 and 75%), specificity (100 and
96.6%), positive predictive value (100 and 81.8%), and negative
predictive value (96.7 and 94.9%). Analysis for objective response
rates and survival were not correlated to IHC staining, although the
combined staining showed nonsignificant trends toward better over-
all survival for patients with EGFR mutations.
Conclusions: The mutation-specific IHC antibodies have high sen-
sitivity and specificity for predefined EFGR mutations and may be
suitable for screening for these predefined mutations. However,
negative IHC results require further mutation analyses before ex-
cluding EGFR-targeted therapy.
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Epidermal growth factor receptor (EGFR) mutation statushas a critical role in the treatment algorithm of advanced
non-small cell lung cancer (NSCLC) in first-, second-, and
third-line therapy. EGFR tyrosine kinase inhibitors (TKIs)
have recently been shown to be superior to chemotherapy in
EGFR-mutated NSCLC patients,1–4 and gefitinib is approved
in Europe for patients harboring EGFR mutations. Therefore,
evaluating the EGFR mutation status is believed to be highly
important before any therapy decision is undertaken in ad-
vanced NSCLC.
Activating mutations in exons 18 to 21 of EGFR were
initially identified in NSCLC patients with clinical response
to gefitinib.5,6 These somatic mutations in the kinase domain
of EGFR exist in approximately 10 to 16% of NSCLC
specimens in the United States and Europe3 and 30 to 50% in
Asia7 with 28 distinct mutations.8,9 The exon 19 deletions
(including E746–A750) account for 45% of the total mu-
tations. Eleven different mutations, resulting in deletion of
three to seven amino acids, have been detected in exon 19,
and all are centered around the uniformly deleted codons for
amino acids 747 to 749. The second major mutation group
observed is the missense mutations found in exon 21 (39–
45%), followed by mutations in exon 20 and 18 (6–10%).
Among the missense mutations in exon 21, the point muta-
tion, L858R, accounts for 39% of the total mutations in exon
21. Patients with EGFR mutations have a greater response
rate to EGFR-TKIs (60–80%) than patients with EGFR
wild-type tumors or unknown mutation status (10–20%).10
Clinically, there seem to be differences in outcome based on
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the type of mutations. Patients with exon 19 deletions dem-
onstrate a higher response rate and longer survival with
EGFR-TKI therapy than patients with point mutations in
exon 21.10–13 EGFR mutations tend to be associated with
adenocarcinoma, East Asian ethnicity, and never smokers.
There are many methods to detect mutations (i.e., DxS
EGFR Mutation Kit (Dxs Ltd., Manchester, UK), high-reso-
lution melting analysis14–16). However, the most common is
direct sequencing of the polymerase chain reaction (PCR)-
amplified exon sequences. Although these methods provide
information about numerous genetic mutations, they are
not always available. Most recently, immunohistochemis-
try (IHC) mutation-specific antibodies have been devel-
oped for EGFR mutations in exons 19 and 21, and encour-
aging data have been presented.17,18 In this study, we tested
the performance of IHC-based methodology to define
EGFR mutation in a retrospective cohort of 70 Japanese
patients and validated the data with DNA sequencing.
PATIENTS AND METHODS
Patients
The study included 70 patients treated with gefitinib as
monotherapy (250 mg/day) for their recurrent diseases after
they had undergone surgery between November 1997 and
July 2007 at the Tokyo Medical University Hospital. Their
clinical characteristics are detailed in Table 1. All patients
were Japanese, aged between 27 and 88 years (mean 59.9
years), 36 (51%) men, 41 (48%) smokers, and 29 (41%)
never smokers. Progression-free survival (PFS) and overall
survival were counted from the time of gefitinib therapy to
progression or death accordingly. The median survival time
was 15.3 months (range 0.1–77.5 months). The median time
to progression was 7.5 months (range 0.1–43.3 months). All
patients had histologically confirmed NSCLC (57 adenocar-
cinoma, 7 squamous cell carcinoma, 4 large cell carcinoma,
and 2 other NSCLC) with measurable, locally advanced or
metastatic disease, progressing or relapsing after the com-
plete resection. On pathologic staging at surgery,19 11 pa-
tients were staged as IA, 10 as IB, 8 as IIA, 3 as IIB, 28 as
IIIA, 7 as IIIB, and 3 as IV.
Assessment of tumor regression was conducted accord-
ing to the RECIST criteria.20 Tumor response for gefitinib
therapy was assessed by computer tomography scan, with a
confirmatory evaluation repeated in patients with complete
response (CR), partial response (PR), stable disease (SD), and
progressive disease at least 4 weeks after the initial determi-
nation of response. During treatment, assessments were per-
formed every 4 weeks for the first 4 months and then every 8
weeks until disease progression. The RECIST20 recom-
mended that duration of SD should specify the minimal time
interval required between two measurements for determina-
tion of SD. Therefore, disease control rate (DCR  CR 
PR SD) was evaluated at 12 weeks. Of the studied patients,
6 (9%) received gefitinib as their first systemic anticancer
therapy after relapse, 33 (47%) received gefitinib as second-
line therapy, and 31 (44%) patients as more than or equal to
third-line therapy. For objective response rate (ORR) calcu-
lation, we considered only patients who were treated by
gefitinib for at least 4 weeks (N  62).
Tissue Microarrays
Tissue microarrays (TMAs) were constructed from the
primary resected tumors according to the procedure described
in the previous reports.21,22 Briefly, the most representative
tumor areas were carefully selected and marked on the
hematoxylin and eosin-stained slide to construct the microar-
rays, and the TMA were assembled using a tissue arraying
instrument (J.M. and T.N., Department of Anatomic Pathol-
ogy, Tokyo Medical University Hospital, Tokyo, Japan).
Samples of the specimens were routinely obtained by collect-
ing three replicate core samples of the tumor (core size of 1.2
mm) from different areas. Normal liver tissues were used for
control and slide orientation purposes.
TABLE 1. Patient Characteristics (n  70)
Characteristics
Total 70 (100)
Age (yr) 59.9 (27–88)
Survival time (mo) 15.3 (0.1–77.5)
Progressive-free survival time (mo) 7.5 (0.1–43.3)
Gender
Male:female 36: 34
Smoking history
Never 29 (41.4)
Smoker 41 (58.6)
Histology
Adenocarcinoma 57 (81.4)
Squamous cell carcinoma 7 (10.0)
Large cell carcinoma 4 (5.7)
Other NSCLC 2 (2.9)
pTNM stagea at surgery
IA 11 (15.7)
IB 10 (14.3)
IIA 8 (11.4)
IIB 3 (4.3)
IIIA 28 (40)
IIIB 7 (10)
IV 3 (4.3)
Type of resection
Bilobectomy 3 (4.3)
Lobectomy 59 (84.3)
Wedge 7 (10)
Tracheoplasty 1 (1.4)
EGFR mutation status
Mutation type 41 (58.6)
exon18 1 (1.4)
exon19 18 (25.7)
exon20 18 (25.7)
exon21 12 (17.1)
Wild-type 29 (41.4)
Data are presented as n (%) or median (range).
a TNM classification 7th edition.19
NSCLC, non-small cell lung cancer; pTNM, pathologic tumor-node-metastasis;
EGFR, epidermal growth factor receptor.
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DNA Sequencing for Detection of Mutations in
the EGFR Gene
Genomic DNA was extracted from tumor surgical speci-
mens in formalin-fixed, paraffin-embedded blocks. Exons 18 to
21 of the TK domain in the EGFR gene were sequenced with the
primers for exon 18: CCTTGTCTCTGTGTTCTTGT (forward),
CTGCGGCCCAGCCCAGAGGC (reverse); exon 19: CATGT-
GGCACCATCTCACA (forward), CCACACAGCAAAGCA-
GAAAC (reverse); exon 20: CTCCCTCCAGGAAGCCTACGT-
GAT (forward), TTTGCGATCTGCACACACCA (reverse); exon
21: CAGGGTCTTCTCTGTTTCAG (forward), TAAAGCCAC-
CTCCTTACTTT (reverse). PCR consisted of 30 cycles with an
annealing temperature of 72°C in a 4.5 l reaction mixture
containing 0.125 l TaKaRa Ex TaqHS, 100 ng template DNA,
and 0.5 l of each primer (SRL, Tachikawa-shi, Tokyo, Japan).
PCR products were then sequenced with a 3100 Genetic Ana-
lyzer (Applied Biosystems, Chuou-ku, Tokyo, Japan).
EGFR Mutation-Specific IHC Staining
Serial 4-m-thick tissue sections were cut from the
TMA for IHC-based EGFR exons 19 and 21 mutation anal-
ysis. Histologic classification was determined on hematoxylin
and eosin-stained sections according to the World Health
Organization criteria.23 The slides were incubated at 55°C
overnight, then deparaffinized in xylene and rehydrated
through a graded series of ethanol concentrations. Slides were
labeled with antibody and protocol-specific bar codes and
loaded into a Benchmark XT (Ventana Medical Systems Inc,
Tucson, AZ) automated stainer. The slides were treated with
Standard Cell Conditioning 1 for 60 minutes (Ventana Med-
ical Systems Inc). The primary antibodies, EGFR E746–
A750del (catalog number 2085), Cell Signaling Technologies
(CST, Danvers, MA) and EGFR L858R (catalog number
3197, CST), were both diluted 1:100 with SignalStain anti-
body diluent (CST) and manually applied to the TMA slides.
The slides were then incubated at 37°C for 1 hour. The
Ultraview Universal DAB detection kit (Ventana Medical
Systems Inc) was used with an extra washing step selected.
The slides were counterstained with hematoxylin and bluing
at 4 minutes each. The slides were washed with mild soapy
water and then dehydrated in ethyl alcohol (Surgipath, Rich-
mond, IL) and Xylene (Surgipath) before applying coverslips.
Scoring Methodology
IHC staining was scored according to the University of
Colorado IHC H-score criteria, with assessment of staining
intensity (0–4) multiplied by the percentage of positive cells
(0–100%) for each intensity for a final IHC score of 0 to 400.
Tumors with H score more than or equal to 20 (i.e., 5%) were
interpreted as positive, and tumors with an H score less than
20 (5%) were interpreted as negative. IHC staining overview
was performed by a pathologist (M.P.) and a trained reader
(Y.K.) at the University of Colorado Cancer Center. The final
score per patient was calculated by the two readers using the
core with the maximum value for each patient.
Statistic Analysis
Standard descriptive statistics and Kaplan-Meier sur-
vival curves were used. Differences in survival were deter-
mined by the log-rank test. Proportions were compared by
means of 2 analysis. The differences were considered to be
statistically significant when the p value is less than 0.05.
SPSS for Windows Version 12.0 (SPSS Inc., Chicago, IL)
was also used to calculate the sensitivity, specificity, and
survival data.
RESULTS
For 70 NSCLC patients, the median interval between
surgery and gefitinib treatment for the recurrence disease was
14.2 months (range 3–82.9 months). The majority of patients
(81.4%) had adenocarcinoma histology. DNA sequencing
mutation analysis showed EGFR mutations in 41 patients
(58.6%): 18 patients (25.7%) had an exon 19 deletion, 18
patients (25.7%) had an exon 20 mutation, 12 patients
(17.1%) had an exon 21 mutation (6 had 2573 TK and 6 had
2573 TG), and one patient (1.4%) had an exon 18 mutation
(Table 1). Among the 18 patients with exon 19 deletion, 7 had
a deletion other than E746–A750 (Table 2). Overlapping
mutations existed between exon 19 and exon 20 (four cases),
exon 20 and exon 21 (three cases), and exon 18 and exon 20
(one case).
EGFR Mutation-Specific Antibody IHC Staining
Expression of EGFR, both E746–A750 deleted and
L858R point mutated, was evaluated in all 70 patients by
IHC. The mutation-specific antibodies have distinct immuno-
reactivity for the plasma membrane of the tumor cells, with
some weak cytoplasmic staining, as presented in Figure 1.
Table 2 summarizes all the cases with either positive direct
sequencing or positive IHC staining. In addition, as tumors
tend to be heterogeneous in their mutational status, Table 3
explores staining intensity over the examined core.
Exon 19 Deletion
IHC staining with the EGFR exon 19 E746–A750
deletion specific antibody was seen in 9 of 11 patients
(Tables 2–4). Because the exon 19-specific antibody was
designed specifically for the E746–A750 deletion, we
considered only those 11 patients who had DNA sequence
verified deletions, 2236 to 2250 or 2235 to 2249, that
resulted in E746–A750 amino acid deletions as sequence
positive. We observed a discrepancy relative to DNA
sequencing in two cases (Cases 4 and 27; Table 2–4). Case
27 had IHC score of 5, but was scored as negative because
of limited staining and the predetermined cutoff of 20.
Case 4 was completely negative by IHC. The sensitivity,
specificity, positive predictive values (PPVs), and the
negative predictive values (NPVs) to detect exon 19
E746–A750 deletions were 81.8, 100, 100, and 96.7%,
respectively (Table 5). If also the other seven deletions
beyond the predefined antibody target were considered, the
sensitivity, specificity, PPV, and NPV were 50, 100, 100,
and 85.2%, respectively (Table 5). The heterogeneity of
staining with the mutation-specific antibodies was evalu-
ated. With regard to the E746–A750-specific antibody, the
areas of poorly differentiated cells were stained more
strongly than well-differentiated areas.
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Exon 21 L858R
Of the 12 EGFR L858R-mutated cases detected by
DNA sequencing, 11 were seen by the EGFR L858R muta-
tion-specific antibody (Tables 2–4). DNA sequencing of
exon 21 showed that nucleotide 2573 was mutated from T to
G in six patients, but in six other patients, it was equivocal if
there was a mutation because both T and G were seen at this
position, thus labeled K. However, all the 12 cases were
considered as L858R mutation based on DNA sequencing
because it was not possible to discriminate the 2573K cases.
Thus, for exon 21-specific L858R mutation, 9 of 12 patients
with EGFR L858R mutation were stained positive by IHC.
However, two other cases showed positive staining discor-
dant with the DNA sequencing (cases 58 and 65, Tables 2–4),
and three cases that showed no IHC staining were discordant
with DNA sequencing (cases 5, 33, and 62). Therefore, the
sensitivity, specificity, PPV, and NPV of the L858R antibody
are 75, 96.6, 81.8, and 94.9%, respectively (Table 5). How-
ever, the two cases of the discordant negative cases (cases 5
and 33, Tables 2 and 3) had a direct sequencing of 2573
TK. Therefore, based on the negative IHC staining, if one
retrospectively classified those patients as negative for EGFR
mutation, the sensitivity, specificity, PPV, and NPV of the
L858R antibody are 90, 96.7, 81.8, and 98.3%, respectively.
The heterogeneity of staining with the L858R-specific anti-
body, poorly differentiated areas, such as the solid central
area, was stronger than well-differentiated areas, such as
those showing lepidic growth.
Focusing on the clinical need to detect any common
EGFR mutations, we calculated the yield of double staining
(E746–A750 and L858R) and found a 78.3% sensitivity and
95.7% specificity for detecting the predefined EGFR muta-
tions and 43.9 and 99.9% to detect any exon19 deletion and
L858R mutation (Table 5).
Clinical Outcome
Sixty-two patients were treated by gefitinib for at least
4 weeks and were considered for outcome analysis (DCR) at
TABLE 2. IHC and Direct Sequencing Details (n  70)
Sample
No. IHC
H Score
(Maximum)
Direct
Sequencing
Nucleotide No.
and Sequence Amino Acid Change
Exon 19 deletions 56 Del 400 Del 2236–2250del15 del E746–A750
49 Del 280 Del 2235–2249del15 del E746–A750
41 Del 230 Del 2235–2249del15 del E746–A750
46 Del 205 Del 2235–2249del15 del E746–A750
69 Del 190 Del 2235–2249del15 del E746–A750
16 Del 110 Del 2235–2249del15 del E746–A750
3 Del 100 Del 2235–2249del15 del E746–A750
43 Del 100 Del 2235–2249del15 del E746–A750
61 Del 100 Del 2235–2249del15 del E746–A750
27 Wt 5 Del 2235–2249del15 del E746–A750
4 Wt 0 Del 2236–2250del15 del E746–A750
42 Wt 0 Del 2239–2253del15a delL747-T751
50 Wt 0 Del 2239–2253del15a delL747-T751
67 Wt 0 Del 2239–2253del15a delL747-T751
24 Wt 0 Del 2240–2257del18a del L747-P753insS
40 Wt 0 Del 2240–2257del18a del L747-P753insS
55 Wt 0 Del 2240–2257del18a del L747-P753insS
18 Wt 0 Del 2253–2276del24a S752-I759
Exon 21 mutations 32 L858R 370 L858R or Wt 2573 TK L858R or Wt
68 L858R 360 L858R 2573 TG L858R
1 L858R 240 L858R 2573 TG L858R
66 L858R 240 L858R 2573 TG L858R
51 L858R 230 L858R or Wt 2573 TK L858R or Wt
31 L858R 200 L858R or Wt 2573 TK L858R or Wt
12 L858R 100 L858R or Wt 2573 TK L858R or Wt
21 L858R 80 L858R 2573 TG L858R
60 L858R 20 L858R 2573 TG L858R
65 L858R 215 Wt
58 L858R 180 Wt
62 Wt 0 L858R 2573 TG L858R
5 Wt 0 L858R or Wt 2573 TK L858R or Wt
33 Wt 0 L858R or Wt 2573 TK L858R or Wt
a Other deletions; L858R  2573 TG, and 2573 TK (K  G or T).
IHC, immunohistochemistry.
Kato et al. Journal of Thoracic Oncology • Volume 5, Number 10, October 2010
Copyright © 2010 by the International Association for the Study of Lung Cancer1554
12 weeks. Among them, 1 (1.6%) had CR, 14 (22.6%) had
PR, 38 (61.3%) had SD as the best response, and 9 (14.5%)
had progressive disease. Overall ORR was 24.2% at 8 weeks.
Analyzing overall and PFS (Figure 2) by positive or negative
IHC staining, for either of the antibodies, produced a nonsig-
nificant trend toward a favorable outcome with positive
staining. Overall, 2- and 5-year survivals with expression of
FIGURE 1. Representative images of epidermal growth fac-
tor receptor expression by immunohistochemical staining
(40 magnification). A, DNA sequence E746–A750 deletion
specimen stained with the E746–A750-specific antibody. Im-
munoreactivity is positive in the tumor cells but absent in
nontumor cells. B, DNA sequence L858R point mutation
case. The tumor cells show no immunoreactivity with the
E746–A750-specific antibody. C, L858R point mutation
tumor showing tumor cells positive for L858R-specific anti-
body. D, E746–A750 mutation case displaying no immuno-
reactivity in the tumor or nontumor cells with the L858R-
specific antibody.
TABLE 3. Immunoreactivity of E746–A750- and L858R-Specific Antibodies
Sample No. IHC Amino Acid Change
H Score
Staining Area (%)
per Intensity
Maximum Mean 0 1 2 3 4
E746–A750-specific antibody 56 Del del E746–A750 400 400 0 0 0 0 100
49 Del del E746–A750 280 225 0 4 68 28 0
41 Del del E746–A750 230 116.7 50 0 33 17 0
46 Del del E746–A750 205 198.3 2 0 96 2 0
69 Del del E746–A750 190 163.3 0 67 13 10 10
16 Del del E746–A750 110 105 0 95 5 0 0
3 Del del E746–A750 100 36.7 65 33 2 0 0
43 Del del E746–A750 100 33.3 67 33 0 0 0
61 Del del E746–A750 100 63.3 37 63 0 0 0
27 Wt (FN) del E746–A750 5 3.33 98 2 0 0 0
L858R-specific antibody 32 L858R L858R or Wt 370 350 0 0 0 50 50
68 L858R L858R 360 256.7 0 0 63 17 20
1 L858R L858R 240 138.3 10 62 8 20 0
66 L858R L858R 240 230 0 0 70 30 0
51 L858R L858R or Wt 230 173.3 0 37 53 10 0
31 L858R L858R or Wt 200 133.3 0 67 33 0 0
12 L858R L858R or Wt 100 66.7 33 67 0 0 0
21 L858R L858R 80 36.7 63 37 0 0 0
60 L858R L858R 20 16.7 83 17 0 0 0
65 L858R (FP) Wt 215 138.3 0 0 94 3 3
58 L585R (FP) Wt 180 146.7 0 55 43 2 0
IHC, immunohistochemistry.
TABLE 4. IHC for E746–A750 and L858R (n  70)
DNA Sequencing for
Exon 19
E746–A750
Other
Deletions Wt
IHC exon 19
Positive 9 0 0 9
Negative 2 7 52 61
11 7 52 70
DNA Sequencing for
Exon 21
L858Ra Wt
IHC exon 21
Positive 9 2 11
Negative 3 56 59
12 58 70
a L858R  2573 TG, and 2573 TK (K  G or T).
IHC, immunohistochemistry.
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dual staining were 61.7 and 36.2% versus 22.9 and 15.7% in
the negative IHC group (not statistically significant), respec-
tively. Two years PFS rate was 47.0 versus 24.4% (not
statistically significant).
To evaluate the contribution of the technology cho-
sen, direct sequencing or mutation-specific IHC, for mak-
ing clinical decisions, we calculated the clinical outcome
for each of the methodologies relative to each of the
relevant mutations (Table 6). When guided by DNA se-
quencing, any of the mutations (all exon 19 deletions,
E746–A750 deletions, and L858R mutations) had signifi-
cantly better ORR and DCR compared with wild-type
cases (Table 6). Conversely, if the decision would have
been made by the mutation-specific IHC technique alone,
no significant differences between the positive and nega-
tive cases would be found. The same holds true when
considering the combination of the two antibodies. This is
because of high ORR among cases with negative staining,
which is most likely related to other types of EGFR
mutations such as in exon 18, exon 20, or exon 19 but
outside the E746–A750 range. Importantly enough, in this
cohort, patients harboring EGFR mutations in exon 20
FIGURE 2. Overall survival (A) and progression-
free survival (B) based on dual mutation-specific
immunohistochemistry staining for E746–A750
and L858R.
TABLE 5. Detection Capabilities for the EGFR Mutation-Specific Antibodies
Sensitivity (%) Specificity (%) Accuracy (%) PPV (%) NPV (%)
E746–A750 81.8 100 97.1 100 96.7
All exon 19 mt 50 100 87.1 100 85.2
L858Ra 75 96.6 92.9 81.8 94.9
E746–A750  L858R 78.3 95.7 90 90 90
Any mutation of all Ex19 mt  L858R 43.9 99.9 64.3 90 54
a Including 2573 TK (K  G or T).
PPV, positive predictive values; NPV, negative predictive values; EGFR, epidermal growth factor receptor.
TABLE 6. Outcome (OS, PFS, RR, and DCR) to Gefitinib Therapy per Mutation Status and Technique
(n  62)
Methods Mutation Status
Total No.
of Patientsa OS (mo) PFS (mo)
ORRb,
n (%) p
DCRc,
n (%) p
DNA sequencing Exon 19 all deletions Mt (n  18) 38.6 12.1 8 (44) 16 (89)
E746–A750 Mt (n  11) 40.8 39.8 4 (36) 10 (91)
L858R (including 2573 TK) Mt (n  11) 34.4 19.9 4 (36) 10 (91)
Exon 18 Mt (n  1) 78 1 (100) 1 (100)
Exon 20 Mt (n  15) 25 23.5 2 (13) 14 (78)
EGFR WT Wt (n  25) 12.9 7.3 1 (4) 0.009 16 (64) 0.057
Specific mutation IHC E746–A750 Mt (n  9) 22.6 11.6 2 (22) 8 (89)
Wt (n  53) 22.1 11.6 13 (25) 0.882 41 (78) 0.691
L858R Mt (n  9) 37.8 19.9 3 (33) 8 (89)
Wt (n  53) 16.8 9.2 12 (23) 0.488 42 (79) 0.499
E746–A750 and L858R Mt (n  18) 34.4 19.9 5 (28) 16 (89)
Wt (n  44) 15.7 8.9 10 (23) 0.673 33 (75) 0.227
p values are between EGFR WT and each of the mutated subtype per section.
a Patients with mutation.
b ORR: Responder  CRPR.
c Disease control rate; CRPRSD 12 wk.
OS, overall survival; PFS, progression-free survival; RR, ●●●; DCR, disease control rate; IHC, immunohistochemistry; EGFR, epidermal growth factor
receptor; WT, wild-type; CR, complete response; PR, partial response; SD, stable disease.
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showed a favorable outcome similar to patients harboring
exon 19 mutation or L858R (Table 6).
DISCUSSION
In this study, we evaluated by IHC the sensitivity, the
specificity, and the association to clinical outcome of novel
mutation-specific antibodies for exon 19 (E746–A750) and
exon 21 (L858R) and compared it with DNA sequencing in a
Japanese cohort with advanced NSCLC. The two EGFR
mutations represent the majority of EGFR mutations in
NSCLC.24 The study demonstrated a high specificity (96%)
and sensitivity (75%; Table 5) to the predetermined muta-
tions, which are targeted by these antibodies.
Recently, Yamamoto et al.25 reported 569 mutations
in 2880 lung cancer patients, and the distribution of EGFR
mutations was as follows: 48.2% of exon 19, 42.7% of
exon 21, 3.7% of exon 20, and 3.2% of exon 18. Together,
exon 19 deletion and exon 21 mutations accounted for
approximately 90% of all EGFR mutations in NSCLC. In
our cohort, 27% of the patients had other mutations than
these two mutation types, mainly (26%) exon 20 mutation.
However, although we know that the E746–A750 and
L858R EGFR mutations in exons 19 and 21 are activating
mutations sensitive to EGFR TKIs, it is not known at this
time whether the other—noncanonical—mutations are sen-
sitive to EGFR TKIs. In this study, however, we showed
that patients harboring EGFR mutations in exon 20 also
had a favorable outcome similar to patients harboring exon
19 mutation or L858R (Table 6).
The mutation-specific antibodies we used in this IHC
study were designed to detect specific mutations, that is,
E746–A750 deletions and L858R point mutations. Indeed, the
sensitivity and the specificity of IHC to detect E746–A750
deletion were 81.8 and 100%, and 75 and 96.6% for L858R,
respectively (or 90 and 96.7% for L858R if considering the
two discussed cases as true negative). However, the IHC
detection of exon 19 mutation covered only 61% of all the
exon 19 cases in our cohort. If screening was performed by
IHC for both L858R and E746–A750 in our cohort, 18 of 70
(26%) of the patients would have been diagnosed as having
EGFR mutation, which represents only 44% of the current
EGFR-mutated cases. Therefore, for clinical decisions, be-
cause any existence of EGFR mutation might be important,
negative IHC will require a validation by other technique
before a clinical decision can be made. Previous studies that
used these antibodies17,18 came to similar conclusions. Yu
et al.17 reported overall sensitivity to detect any EGFR
mutation in 340 tumors of 92% and specificity of 99%,
however, the rate of other EGFR mutations was relatively
low in their cohort. Brevet et al.18 just recently reported
sensitivity of 85% to detect exon 19 deletion and of 95%
to detect L858R point mutations in exon 21. Our data
support these studies and are the first to associate this
method with the clinical outcome, where positive anti-
body-specific IHC staining, for either of the antibodies,
was associated with a nonsignificant trend toward a favor-
able outcome with positive staining (Figure 2).
IHC is a well-established method routinely applied in
lung cancer diagnosis in clinical laboratories. IHC also leads
for the simultaneous analysis of expression level of other
proteins or protein modifications. IHC also allows for the
analysis of small tissue samples or cytologic samples (body
fluids, bronchial washings, and fine needle aspirates samples)
and circulating tumor cells.26 Thus, the detection of E746–
A750 and L858R EGFR protein-specific mutations by IHC
would be a valuable addition to the current protocols used in
the diagnosis and treatment of lung cancer and particularly
useful for mass screening of NSCLC patients for EGFR
mutations.
Recently, many studies have reported simple and
highly sensitive nonsequencing methods for detecting
EGFR mutations in small tumor tissue samples26–29 in
addition to cytologic specimens (pleural effusion, aspira-
tion cytologic specimens).30–34 These methods are reported
to be quick and convenient. However, these methods have
limitations, for example, many, if not all, biopsy speci-
mens will also contain noncancerous lesions (e.g., scar
lesion, inflammation, peripheral pre cancerous lesions).
The aforementioned methods cannot distinguish between
the cancerous and noncancerous materials unless the tumor
cells are microdissected, whereas the IHC can be viewed
by a pathologist, who discriminates the tissues and assess
the cancer cells per se.
The discrepant results between IHC and DNA sequenc-
ing found in this study may result from differences in sample
size of the TMA cores versus the large specimens used for
DNA sequencing. In our study, we used TMAs, whereas in
previous studies,17,18 specimens from the whole paraffin-
embedded blocks were used. Thus, a much smaller quantity of
tumor specimen was used in our study. EGFR mutations may
not be homogeneously dispersed throughout the tumor, so that
even though a core contains tumor cells, it may randomly
include only wild-type EGFR and miss mutation positive tumor
cells compared with whole section assessment.
The limitation of our study pertaining to the clinical
outcome analysis may be due to the heterogeneity of the
studied clinical cohort, with regard to type of disease
recurrence and line gefitinib treatment. Therefore, even
though we have analyzed the outcome per line of therapy
(data not shown), still, this is not an optimal cohort for
analyzing the predictive performance of IHC to the clinical
outcome. Likewise, we had a high rate of exon 20 (18/70;
26%) mutations, which decreased the power of the test to
predict the clinical outcome, because patients harboring
exon 20 EGFR mutation showed a better response to
gefitinib in our cohort.
In summary, the accuracy of the used mutation-specific
IHC for E746–A750 and L858R is high for predefined EGFR
mutations. We believe that IHC is suitable for screening
NSCLC patients for existence of these predefined EGFR
mutations, but negative results should be validated further
before excluding them from EGFR-related therapy. Such IHC
method might provide faster and wider test availability,
requires less tumor material, allow histologic evaluation, and
is more cost differential for a positive test.
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